Aterosclerosis acelerada en vasculitis asociada a anticuerpos anticitoplasma de neutrófilos: reporte de caso

Natalia Andrea Uribe Ruíz; María Paulina Villa; Alberto  Álzate Gutiérrez; Clara Inés Saldarriaga Giraldo; José Gregorio  Thorrens Ríos

doi:10.47487/apcyccv.v5i1.331

Authors

Natalia Andrea Uribe Ruíz Universidad de Antioquia, Medellín, Colombia. https://orcid.org/0000-0003-0929-7843
María Paulina Villa Universidad Pontificia Bolivariana, Medellín, Colombia. https://orcid.org/0000-0003-2800-8867
Alberto Álzate Gutiérrez Universidad de Antioquia, Medellín, Colombia. https://orcid.org/0009-0000-7520-660X
Clara Inés Saldarriaga Giraldo Clínica Cardio VID, Medellín, Colombia. https://orcid.org/0000-0002-5945-1127
José Gregorio Thorrens Ríos Clínica Cardio VID, Medellín, Colombia. https://orcid.org/0000-0002-9756-7569

DOI:

https://doi.org/10.47487/apcyccv.v5i1.331

Keywords:

Atherosclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Myocardial Infarction

Abstract

Accelerated atherosclerosis has become a complication of multiple autoimmune diseases, among which Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis stands out. The case of a patient with hypertension, diabetes, and chronic kidney disease of unknown etiology is described, who presented two acute coronary syndromes with a difference of only six months, with rapid progression of coronary involvement, in search of the etiology with an increase in inflammatory response markers, tomography with usual interstitial pneumonia and positive antibodies directed against myeloperoxidase (anti-MPO) that led to the diagnosis of microscopic polyangiitis (PAM). The situation in which a timely diagnostic suspicion is crucial since early treatment has a notable impact on the course and prognosis of the disease.

Downloads

Download data is not yet available.

References

Floyd L, Morris AD, Woywodt A, Dhaygude A. Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat? Clin Kidney J. 2022;15(4):618-623. doi: 10.1093/ckj/sfac009.

Markousis-Mavrogenis G, Pepe A, Gargani L, Kariki U, Bonou M, Koutsogeorgopoulou L, et al. Myocardial Involvement in Rheumatic Disorders. Curr Heart Fail Rep. 2020;17(5):171-180. doi: 10.1007/s11897-020-00471-1.

Clifford AH, Cohen Tervaert JW. Cardiovascular events and the role of accelerated atherosclerosis in systemic vasculitis. Atherosclerosis. 2021;325:8-15. doi: 10.1016/j.atherosclerosis.2021.03.032.

Zanatta E, Colombo C, D’Amico G, d’Humières T, Dal Lin C, Tona F. Inflammation and Coronary Microvascular Dysfunction in Autoimmune Rheumatic Diseases. Int J Mol Sci. 2019;20(22):5563. doi: 10.3390/ijms20225563.

Bacon PA, Stevens RJ, Carruthers DM, Young SP, Kitas GD. Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev. 2002;1(6):338-47. doi: 10.1016/s1568-9972(02)00100-3.

Houben E, Penne EL, Voskuyl AE, van der Heijden JW, Otten RHJ, Boers M, et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology (Oxford). 2018;57(3):555-562. doi: 10.1093/rheumatology/kex338.

Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015;36(8):482-9c. doi: 10.1093/eurheartj/ehu403.

Terrier B, Chironi G, Pagnoux C, Cohen P, Puéchal X, Simon A, et al. French Vasculitis Study Group. Factors associated with major cardiovascular events in patients with systemic necrotizing vasculitides: results of a longterm followup study. J Rheumatol. 2014;41(4):723-9. doi: 10.3899/jrheum.130882.

Swets BP, Brouwer DA, Tervaert JW. Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin Exp Immunol. 2001;124(1):163-7. doi: 10.1046/j.1365-2249.2001.01488.x.

Pagnoux C, Chironi G, Simon A, Guillevin L. Atherosclerosis in ANCAassociated vasculitides. Ann N Y Acad Sci. 2007;1107:11-21. doi: 10.1196/annals.1381.002.

Chironi G, Pagnoux C, Simon A, Pasquinelli-Balice M, Del-Pino M, Gariepy J, et al. Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis. Heart. 2007;93(1):96-9. doi: 10.1136/hrt.2006.088443.

González-Suárez I, Ríos-Blanco JJ, Arpa J. Accelerated atherosclerosis in ANCA-associated vasculitis. Acta Neurol Scand. 2017;136(6):688-693. doi: 10.1111/ane.12787.

De Leeuw K, Kallenberg C, Bijl M. Accelerated atherosclerosis in patients with systemic autoimmune diseases. Ann N Y Acad Sci. 2005;1051:362-71. doi: 10.1196/annals.1361.078.

Cohen Tervaert JW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol. 2013;27(1):33-44. doi: 10.1016/j.berh.2012.12.004.

Bramlage CP, Kröplin J, Wallbach M, Minguet J, Smith KH, Lügders S, et al. Management of cardiovascular risk factors in patients with ANCA-associated vasculitis. J Eval Clin Pract. 2017;23(4):747-754. doi: 10.1111/jep.12709.